Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 6407   Home Print this page  Email this page Small font size Default font size Increase font size
Year : 1993  |  Volume : 11  |  Issue : 2  |  Page : 33-36

Value Of Pyrazinamide In Initial Intensive Phase Of Long-Term Retreatment For Pulmonary Tuberculosis Patients With Primary Treatment Failure

Correspondence Address:
S Rajasekaran

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Conventional 12 or 18-month anti-tuberculous drug regimens (SH-B/W, STH + TH) continue to be primary treatment schedules in majority of the patients in the District Tuberculosis Programme in India. Pulmonary tuberculosis patients falled to one of these regimens were retreated with two drug formulations, i.e., 1ERZ + 11E2 R2 and 2ERZ + 10 E2 R2. Sputum conversion rates at the end of two months treatment were 91% and 92% respectively. The relapse rates had been 5.2% and 4.8% respectively at the end of one year follow-up. Thus, Pyrazinmide administration (during initial intensive phase) beyond one month did not offer any additional benefit.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded83    
    Comments [Add]    

Recommend this journal